Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 96,517
  • Shares Outstanding, K 11,171
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,200 K
  • 60-Month Beta 1.73
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ANVS with:

Options Overview Details

View History
  • Implied Volatility 120.16% ( -0.66%)
  • Historical Volatility 74.07%
  • IV Percentile 8%
  • IV Rank 12.32%
  • IV High 472.50% on 12/13/23
  • IV Low 70.66% on 08/01/24
  • Put/Call Vol Ratio 2.49
  • Today's Volume 401
  • Volume Avg (30-Day) 521
  • Put/Call OI Ratio 1.59
  • Today's Open Interest 28,624
  • Open Int (30-Day) 27,569

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.63
  • Number of Estimates 2
  • High Estimate -0.38
  • Low Estimate -0.89
  • Prior Year -1.63
  • Growth Rate Est. (year over year) +61.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.45 +13.69%
on 09/06/24
9.98 -15.15%
on 08/23/24
-0.45 (-5.04%)
since 08/20/24
3-Month
4.53 +86.98%
on 07/02/24
17.88 -52.63%
on 07/09/24
+2.44 (+40.46%)
since 06/20/24
52-Week
4.53 +86.98%
on 07/02/24
22.49 -62.34%
on 12/27/23
-2.14 (-20.17%)
since 09/20/23

Most Recent Stories

More News
Annovis Bio (NYSE: ANVS) to Participate at H.C. Wainwright Investment Conference

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced...

ANVS : 8.47 (-1.97%)
Annovis Bio (NYSE: ANVS) Expands Team in Continued Focus to Make Meaningful Impact on Lives of AD, PD Patients

Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s...

ANVS : 8.47 (-1.97%)
Annovis Bio (NYSE: ANVS) CEO Discusses Findings of Buntanetap Alzheimer’s Study on Bell2Bell Podcast

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, presented significant data and findings of its Phase 2/3 Alzheimer’s...

ANVS : 8.47 (-1.97%)
Annovis Bio (NYSE: ANVS) Announces Q2 2024 Financial Results

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today released...

ANVS : 8.47 (-1.97%)
Annovis Bio’s (NYSE: ANVS) Lead Compound Shows Synergistic Cognitive Enhancement

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, announced new preclinical data demonstrating lead compound buntanetap’s potential to synergistically enhance cognition when used...

ANVS : 8.47 (-1.97%)
Annovis Bio (NYSE: ANVS) Secures U.S. Patent Covering Methods For Treating TBI, Preventing Nerve Cell Death With Buntanetap

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, announced the issuance of a U.S. patent for treating traumatic brain injury (“TBI”) with its lead drug candidate, buntanetap....

ANVS : 8.47 (-1.97%)
Annovis Bio (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 8.47 (-1.97%)
MRK : 117.17 (-0.05%)
SNY : 57.63 (-1.08%)
JNJ : 164.16 (-0.40%)
NVS : 115.94 (-0.03%)
Annovis Bio (NYSE: ANVS) Releases Promising Clinical Data As Alzheimer’s Therapeutics Market Grows

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 8.47 (-1.97%)
PFE : 29.42 (-0.81%)
LLY : 921.49 (+0.70%)
GSK : 40.80 (-1.97%)
NVO : 127.51 (-5.46%)
Annovis Bio (NYSE: ANVS) Reports on Clinical Data Showing Lead Compound Combined with GLP-1 Agonist Enhances Cognition

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 8.47 (-1.97%)

Business Summary

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 9.08
2nd Resistance Point 8.95
1st Resistance Point 8.71
Last Price 8.47
1st Support Level 8.34
2nd Support Level 8.21
3rd Support Level 7.97

See More

52-Week High 22.49
Fibonacci 61.8% 15.63
Fibonacci 50% 13.51
Fibonacci 38.2% 11.39
Last Price 8.47
52-Week Low 4.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar